Skip to main content
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 2023 May 15;133(10):e171901. doi: 10.1172/JCI171901

RGS2-mediated translational control mediates cancer cell dormancy and tumor relapse

Jaebeom Cho, Hye-Young Min, Ho Jin Lee, Seung Yeob Hyun, Jeong Yeon Sim, Myungkyung Noh, Su Jung Hwang, Shin-Hyung Park, Hye-Jin Boo, Hyo-Jong Lee, Sungyoul Hong, Rang-Woon Park, Young Kee Shin, Mien-Chie Hung, Ho-Young Lee
PMCID: PMC10178829  PMID: 37183821

Original citation: J Clin Invest. 2021;131(1):e136779. https://doi.org/10.1172/JCI136779

Citation for this corrigendum: J Clin Invest. 2023;133(10):e171901. https://doi.org/10.1172/JCI171901

The authors recently became aware of an inadvertent error in Figure 3E. In the original version of Figure 3E, the H1299 Cyclin D1 blot was incorrect and was the same as the SK Cyclin D1 blot. The correct figure is shown below. The HTML and PDF versions have been updated online.

graphic file with name jci-133-171901-g159.jpg

The authors regret the error.

Version 1. 05/15/2023

Electronic publication

Footnotes


Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES